Krystal Biotech (KRYS) Enterprise Value (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Enterprise Value of -$845.6 million for Q2 2026, down 24.0% year-over-year from -$1.1 billion in Q2 2025, and down 2.7% on a QoQ basis from -$823.4 million in Q1 2026.
Krystal Biotech (KRYS) Enterprise Value (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Enterprise Value for 11 years, with the latest figure at -$845.6 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$845.6 million, down 24.0% year-over-year; the trailing twelve-month figure through Jun 2026 was -$845.6 million (down 24.0% YoY), and the FY2025 annual result was -$827.8 million, down 38.54% from the prior year.
- Enterprise Value retreated to -$845.6 million in Q2 2026, from -$823.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$350.4 million in Q1 2023 and troughed at -$845.6 million in Q2 2026.
- A 5-year average of -$575.9 million and a median of -$560.8 million in 2023 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2023, when Enterprise Value increased 19.38%; it then plunged 53.62% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$379.2 million in 2022, then slumped by 40.35% to -$532.2 million in 2023, then retreated by 12.28% to -$597.5 million in 2024, then slumped by 38.54% to -$827.8 million in 2025, then slipped by 2.16% to -$845.6 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$845.6 million in Q2 2026, -$823.4 million in Q1 2026, and -$827.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | -845.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -845.63 Mn |
| Mar 31, 2026 | -823.41 Mn |
| Dec 31, 2025 | -827.79 Mn |
| Sep 30, 2025 | -731.07 Mn |
| Jun 30, 2025 | -681.99 Mn |
| Mar 31, 2025 | -616.85 Mn |
| Dec 31, 2024 | -597.52 Mn |
| Sep 30, 2024 | -588.32 Mn |
| Jun 30, 2024 | -559.61 Mn |
| Mar 31, 2024 | -538.26 Mn |
| Dec 31, 2023 | -532.18 Mn |
| Sep 30, 2023 | -562.07 Mn |
| Jun 30, 2023 | -477.52 Mn |
| Mar 31, 2023 | -350.39 Mn |
| Dec 31, 2022 | -379.17 Mn |
| Sep 30, 2022 | -394.42 Mn |
| Jun 30, 2022 | -425.57 Mn |
| Mar 31, 2022 | -434.63 Mn |
| Dec 31, 2021 | -438.10 Mn |
| Sep 30, 2021 | -343.09 Mn |